US FDA approves bi-weekly teclistamab dosing in relapsed/refractory myelomaAccess, MPE, MyelomaFebruary 22, 2024
EMA CHMP confirms recommendation for non-renewal of Blenrep marketing authorisationAccess, MPEDecember 15, 2023
MPE launches European Amyloidosis Diagnosis Pathway to promote early detection of the rare diseaseAccess, AL amyloidosisOctober 26, 2023
Selinexor receives positive opinion from the EMA for the treatment of refractory myelomaAccess, MyelomaJanuary 30, 2021
EMA recommends conditional marketing authorisation in Europe for teclistamab for relapsed and refractory myelomaAccess, MyelomaJuly 28, 2022
Daratumumab subcutaneous, first approved treatment for newly diagnosed AL amyloidosis in EuropeAccess, AL amyloidosisJune 23, 2021
European Commission approves the second indication of isatuximab for relapsed multiple myelomaAccess, MyelomaApril 19, 2021
Selinexor receives Conditional Marketing Authorisation in Europe for the treatment of relapsed and or refractory myeloma patientsAccess, MyelomaMarch 30, 2021
